OnKure Therapeutics (NASDAQ:OKUR) Given New $30.00 Price Target at Oppenheimer

OnKure Therapeutics (NASDAQ:OKUR) had its price objective trimmed by Oppenheimer from $35.00 to $30.00 in a report issued on Tuesday,Benzinga reports. The firm currently has an outperform rating on the stock.

OKUR has been the topic of several other research reports. Leerink Partnrs raised shares of OnKure Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Leerink Partners initiated coverage on OnKure Therapeutics in a report on Thursday, December 5th. They set an “outperform” rating and a $33.00 price objective for the company. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, OnKure Therapeutics presently has an average rating of “Buy” and an average price target of $34.33.

OnKure Therapeutics Stock Down 3.5 %

OKUR opened at $4.62 on Tuesday. The stock has a market cap of $15.44 million, a P/E ratio of -0.38 and a beta of 0.28. OnKure Therapeutics has a 1 year low of $4.55 and a 1 year high of $20.00. The business’s fifty day moving average price is $5.82.

OnKure Therapeutics (NASDAQ:OKUR) last issued its quarterly earnings results on Monday, March 10th. The company reported ($1.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.51). As a group, sell-side analysts forecast that OnKure Therapeutics will post -4.05 EPS for the current fiscal year.

Institutional Investors Weigh In On OnKure Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Acorn Capital Advisors LLC bought a new stake in shares of OnKure Therapeutics during the fourth quarter valued at about $12,381,000. Citadel Advisors LLC purchased a new position in OnKure Therapeutics during the fourth quarter valued at approximately $8,782,000. Samsara BioCapital LLC bought a new position in OnKure Therapeutics in the 4th quarter valued at $7,088,000. Vestal Point Capital LP purchased a new position in shares of OnKure Therapeutics during the 4th quarter valued at $5,461,000. Finally, Deep Track Capital LP bought a new position in shares of OnKure Therapeutics in the fourth quarter worth $4,506,000. Hedge funds and other institutional investors own 90.98% of the company’s stock.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.